Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Adac Labs

This article was originally published in The Gray Sheet

Executive Summary

Adac Labs: Firm's MCD/ACTM (Molecular Coincidence Detection with Attenuation Correction) technology receives 510(k) clearance, permitting the firm to add the distortion-reducing feature to its nuclear medicine imaging systems. By correcting for "image distortions created by non-uniform attenuation of soft tissue in the human body," MCD/ACTM permits Adac's systems to perform both single photon emission computed tomography and coincidence imaging, the company explains...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts